Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$103.46 - $126.29 $98.9 Million - $121 Million
955,706 Added 658.65%
1,100,806 $118 Million
Q4 2022

Feb 14, 2023

BUY
$36.06 - $117.21 $5.23 Million - $17 Million
145,100 New
145,100 $16 Million

Others Institutions Holding RXDX

About Prometheus Biosciences, Inc.


  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Farallon Capital Management LLC Portfolio

Follow Farallon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.